Derbal Youcef
Ted Rogers School of Information Technology Management, 7984Ryerson University, Toronto, ON, Canada.
Health Informatics J. 2022 Apr-Jun;28(2):14604582221102314. doi: 10.1177/14604582221102314.
Artificial intelligence (AI) powered by the accumulating clinical and molecular data about cancer has fueled the expectation that a transformation in cancer treatments towards significant improvement of patient outcomes is at hand. However, such transformation has been so far elusive. The opacity of AI algorithms and the lack of quality annotated data being available at population scale are among the challenges to the application of AI in oncology. Fundamentally however, the heterogeneity of cancer and its evolutionary dynamics make every tumor response to therapy sufficiently different from the population, machine-learned statistical models, challenging hence the capacity of these models to yield reliable inferences about treatment recommendations that can improve patient outcomes. This article reviews the nominal elements of clinical decision-making for precision oncology and frames the utility of AI to cancer treatment improvements in light of cancer unique challenges.
由不断积累的癌症临床和分子数据驱动的人工智能(AI),让人们燃起了期待,即癌症治疗即将朝着显著改善患者预后的方向转变。然而,迄今为止这种转变仍难以实现。人工智能算法的不透明性以及在人群规模上缺乏高质量的标注数据,是人工智能在肿瘤学应用中的挑战之一。然而,从根本上说,癌症的异质性及其进化动态使得每个肿瘤对治疗的反应都与总体情况、机器学习的统计模型有足够大的差异,从而挑战了这些模型做出可靠的治疗建议推断以改善患者预后的能力。本文回顾了精准肿瘤学临床决策的关键要素,并根据癌症的独特挑战阐述了人工智能对改善癌症治疗的作用。